Breaking up with Pfizer is hard to do, Zoetis chief says, but worth it

Tracy Staton Why do Russians prefer cats to dogs? Which livestock drugs are growing fastest? And what are the benefits of being separate from Pfizer? FiercePharma News

Shire Buying ViroPharma Expected to Add $831 Million in Revenue by 2018

mia.burns By Mia Burns (mia.burns@ubm.com) Not only is Shire plc’s move to purchase ViroPharma for $ 50 a share, in a transaction worth a considerable $ 4.2 billion the largest ...

Argos rakes in $17.5M more to wrap up PhIII for cancer drug

Damian Garde Argos Therapeutics is working to get out from under the shadow of Dendreon and its disappointing Provenge, and now the North Carolina company has the cash it needs to get ...

Actavis cutting 30% of U.S. sales organization

Eric Palmer Actavis began tallying up just how many bodies it needed in its U.S. sales organization as soon as it closed Oct. 1 on its $ 8.5 billion merger with Warner Chilcott.  FiercePharma ...

New UK mHealth Congress Announced for 2014

mia.burns MCT-Congress will bring together key influencers to drive the business of mHealth in clinical research 18 November 2013 – Edinburgh, Scotland – MCT-Congress ...

GlaxoSmithKline politely dumps $230M Fabry drug deal with Amicus

John Carroll Slightly less than a year after GlaxoSmithKline and Amicus Therapeutics reported that the first step in their Phase III program for the Fabry disease drug Amigal–or ...

Dompé Carries out Internationalization Plan

mia.burns By (mia.burns@ubm.com) Dompé, S.p.A, an Italian pharma company based in Milan, is setting its sights on New York with new offices. Associate Web Editor Mia Burns interviewed ...

Daiichi’s a-fib drug aces PhIII, faces crowded market

Damian Garde Daiichi Sankyo's atrial fibrillation-treating edoxaban posted promising results in Phase III, matching the stroke-prevention prowess of warfarin with a better safety ...

Adcock investor complains to Johannesburg exchange about CFR deal

Tracy Staton Chile's CFR Pharmaceuticals faces one more obstacle in its bid for the South African drugmaker Adcock Ingram. After wooing Adcock for months, the Chilean company now ...

Voltarra Pharmaceuticals Appoints CEO

mia.burns Voltarra Pharmaceuticals Appoints Richard P. Becker, Jr. CEO Newly Formed Lehigh Valley Biotech Introduces Clinical Pipeline at Life Sciences Future BETHLEHEM, Pa. (November ...

Relax, PCSK9ers: FDA won’t roadblock blockbusters from Sanofi, Amgen

Damian Garde On the heels of new guidelines casting doubts on a much-hyped new class of cholesterol drugs, the FDA said it would not demand long and costly outcomes trials before approving ...

Pfizer gives the raspberry to BlackBerry

Eric Palmer Pfizer, which sells the hemophilia drug Xyntha, last year rolled out its HemMobile app to build its relationship with patients who use its treatments. The fact ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS